Blockbuster product "Hernix" has successfully launched by Beacon for Early stage HER2 Breast Cancer patients

BEACON introduced another promising multiple Tyrosine kinase inhibitor, Cabozanitib, under the brand name of Cabozanix for global market.Blockbuster product "Hernix" has successfully launched by Beacon for Early stage HER2 Breast Cancer patients

Hernix is a kinase inhibitor indicated for

• Treatment of adult patients with early stage HER2 overexpressed breast cancer.

• Hernix can reduce risk of recurrence following Tastuzumab based therapy.

• Improve disease free survival

• Significant treatment benefit at 5 years.

It is an oral tablet production available in the strength of 40 mg.

This product is only for export..

To know more visit our website: www.Hernix.com.bd